Clinical Trials on Influenza and Acute Respiratory Viral Infections in Japan

Total 415 results

University of Shizuoka

Unknown

Gargling With Green Tea for Prophylaxis of Influenza Infection in Teenagers

Influenza Infection

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Exploratory Clinical Study of MT-2301

Haemophilus Influenza Type b

Japan
University of Shizuoka
Hamamatsu University; Seirei Hamamatsu General Hospital

Completed

Catechin Containing Mask for the Prevention of Influenza Infection

Influenza Infection

Japan
Masahiro Morikawa
White Cross Nursing Home

Completed

Effects of Tea Catechin Consumption on the Prophylaxis of Influenza Infection

Influenza Infection

Japan
University of Shizuoka
White Cross Nursing Home; Seirei Hamamatsu General Hospital; Shizuoka General...

Completed

Catechin Gargling for Influenza Infection

Influenza Infection

Japan
Institute for Clinical Effectiveness, Japan
GlaxoSmithKline

Recruiting

Effect of Respiratory Virus Infection on EmeRgencY Admission Study (EVERY Study) (EVERY)

Acute Disease | Respiratory Syncytial Virus (RSV) | Respiratory Viral Infection

Japan
Novartis Vaccines

Completed

Open-label, Uncontrolled Postmarketing Study of Cell-derived A/H1N1 Influenza HA Vaccine in Japanese Elderly Subjects

Swine-Origin Influenza A H1N1 Virus

Japan
Novartis Vaccines

Completed

Single-blind, Dose-ranging Study of Novel Swine Influenza Virus Vaccine in Japanese Pediatric Subjects

Swine-Origin Influenza A H1N1 Virus

Japan
UMN Pharma Inc.

Completed

Immunogenicity and Safety Study of a Booster Vaccination With a Recombinant H5N1 Influenza HA Vaccine in Primed Adults

Influenza

Japan
GlaxoSmithKline

Completed

Study of GSK Biologicals' Influenza Vaccine Arepanrix™ in Japanese Adults 65 Years of Age or Older

Influenza

Japan
Nitto Denko Corporation

Completed

Evaluation of the Safety and Immunogenicity of a Sublingual Influenza Vaccine NSV0001 in Healthy Male Volunteers

Influenza

Japan
Rohto Pharmaceutical Co., Ltd.

Completed

An Exploratory Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection (COVID-19)

Severe Acute Respiratory Syndrome Coronavirus 2

Japan
GlaxoSmithKline

Completed

Safety and Immunogenocity Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Japanese Children

Influenza

Japan
Novartis Vaccines

Completed

Drug Use Investigation for Cell-culture Derived Influenza A (H1N1) Emulsion HA Vaccine

Swine-Origin Influenza A H1N1 Virus

Japan
UMN Pharma Inc.

Completed

A Study to Assess the Safety of ASP7374 in Adult Subjects Aged 20 or Older

Influenza | Vaccine

Japan
UMN Pharma Inc.

Completed

A Study to Evaluate Intramuscular ASP7374

Influenza | Vaccine

Japan
GlaxoSmithKline

Completed

Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1)

Influenza

Japan
Novartis Vaccines

Completed

Single-blind, Dose-ranging Study of Novel Swine Influenza Virus Vaccine in Japanese Adult Subjects

Influenza

Japan
GlaxoSmithKline

Completed

Immunogenicity and Safety of GSK Biologicals' (Pre-) Pandemic Influenza Candidate Vaccine

Influenza

Japan
Sanofi Pasteur, a Sanofi Company
Sanofi K.K.

Completed

Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Patients ≥65 Years

Influenza

Japan
UMN Pharma Inc.

Completed

Study of ASP7374, Cell-culture-derived Influenza Vaccine

Influenza | Vaccine

Japan
UMN Pharma Inc.

Completed

Phase-3 Study of ASP7374, Cell-culture-derived Influenza Vaccine

Influenza

Japan
UMN Pharma Inc.

Completed

Immunogenicity, Safety and Optimal Dose Finding Study of Recombinant Influenza H5N1 Vaccine in Healthy Young Adults

Virus Diseases | Influenza

Japan
Takeda

Completed

A Study of TAK-019 in Healthy Japanese Adults (COVID-19)

Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)

Japan
Ology Bioservices
Baxter Innovations GmbH

Completed

Japanese Pediatric H5N1 Vaccine Study

Influenza

Japan
Ology Bioservices

Completed

H5N1 Vaccine Study in Japanese Elderly Population Aged 65 Years and Older

Influenza

Japan
Takeda

Completed

Phase 1/2 Study of TAK-850 Intramuscular Injection in Healthy Pediatric Participants

Influenza Infection

Japan
Ology Bioservices
Baxter Innovations GmbH

Completed

H5N1 Vaccine Study in Japanese Adults

H5N1 Influenza

Japan
GlaxoSmithKline

Completed

A Study of Intravenous Zanamivir in the Treatment of Hospitalized Patients With Influenza Infection

Influenza, Human

Japan
Takeda

Completed

A Phase 1/2 Study of a Intramuscular Injection of TAK-850 in Healthy Adult Subjects

Influenza

Japan
Sanofi Pasteur, a Sanofi Company

Completed

Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older

Healthy Volunteers | Influenza Immunization

Japan
Kameda Medical Center
Merck Sharp & Dohme LLC; PPD; Osaka University

Completed

The Immunogenicity of Simultaneous Administration of Quadrivalent Influenza Vaccine and 23-valent Pneumococcal Vaccine

Influenza | Pneumococcal Pneumonia

Japan
GlaxoSmithKline

Completed

Phase1 Study of GR121167, Single and Multiple Dose Study in Healthy Japanese Males

Influenza, Human

Japan
Takeda

Withdrawn

A Phase 2 Study of a Subcutaneous Injection of TAK-850 in Healthy Adult Participants

Influenza Prevention

Japan
Takeda

Completed

A Phase 4 Post-marketing Study of Intramuscular Injections of BLB-750 in Healthy Adult Subjects

Pandemic Influenza Prevention

Japan
Nobelpharma

Terminated

NPC-06 to Acute Pain in Herpes Zoster

Acute Pain in Herpes Zoster

Japan
Pfizer

Completed

A Study to Learn About PAXLOVID (a Commercial Medicine) In People With COVID-19

SARS-CoV-2 Infection

Japan
Rohto Pharmaceutical Co., Ltd.

Completed

A Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection (COVID-19)

SARS-CoV-2 Infection( COVID-19 )

Japan
Daiichi Sankyo Co., Ltd.

Completed

A Multinational Phase III Study of CS-8958 (MARVEL) (MARVEL)

Influenza, Human

Taiwan, Japan, Korea, Republic of, China
AnGes, Inc.
Japan Agency for Medical Research and Development

Completed

Phase I/II Study of COVID-19 DNA Vaccine (AG0302-COVID19 High-dose)

COVID-19 Lower Respiratory Infection

Japan
BioNTech SE
Pfizer

Completed

Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Japanese Adults

COVID-19 | SARS-CoV-2 Infection

Japan
University of Minnesota
National Institute of Allergy and Infectious Diseases (NIAID); National Institutes...

Completed

Respiratory Virus Outpatient Study (FLU 002 Plus)

Influenza and Other Novel Respiratory Viruses

United States, Chile, United Kingdom, Spain, Argentina, Australia, Thailand, Peru, Germany, Japan, Greece, Belgium, Denmark, Estonia, Poland
Takeda

Completed

Phase III Study of Intramuscular TAK-816 in Healthy Infants

Healthy Volunteers | Haemophilus Influenzae Type b, Prevention

Japan
AstraZeneca

Terminated

VAXZEVRIA Japan Post-Marketing Surveillance (PMS) for the Subjects With Underlying Disease at High-risk for Worsening COVID-19

Prevention of Infectious Disease Caused by SARS-CoV-2

Japan
AstraZeneca

Completed

An Observational Study to Describe EVUSHELD™ (Tixagevimab/Cilgavimab) Pre-exposure Prophylaxis in Real-world Setting in Japan (Evusheld DBR)

COVID-19

Japan
Pfizer

Completed

Special Investigation of COMIRNATY in the Population With Underlying Diseases

COVID-19

Japan
AnGes, Inc.

Completed

Study of COVID-19 DNA Vaccine (AG0302-COVID19)

COVID-19

Japan
AnGes, Inc.
Japan Agency for Medical Research and Development

Completed

Study of COVID-19 DNA Vaccine (AG0301-COVID19)

COVID-19

Japan
Pfizer

Completed

Drug Use Investigation of COMIRNATY Intramuscular Injection

COVID-19

Japan
Medicago
Mitsubishi Tanabe Pharma Corporation

Terminated

Safety Immunogenicity Study of MT-2766 in Japanese Adults（COVID-19）

SARS-CoV-2 Infection

Japan

3

Subscribe